JP2015501645A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501645A5
JP2015501645A5 JP2014546169A JP2014546169A JP2015501645A5 JP 2015501645 A5 JP2015501645 A5 JP 2015501645A5 JP 2014546169 A JP2014546169 A JP 2014546169A JP 2014546169 A JP2014546169 A JP 2014546169A JP 2015501645 A5 JP2015501645 A5 JP 2015501645A5
Authority
JP
Japan
Prior art keywords
mir
cancer cells
mammalian cancer
increasing
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068736 external-priority patent/WO2013086489A1/en
Publication of JP2015501645A publication Critical patent/JP2015501645A/ja
Publication of JP2015501645A5 publication Critical patent/JP2015501645A5/ja
Pending legal-status Critical Current

Links

JP2014546169A 2011-12-10 2012-12-10 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法 Pending JP2015501645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569237P 2011-12-10 2011-12-10
US61/569,237 2011-12-10
PCT/US2012/068736 WO2013086489A1 (en) 2011-12-10 2012-12-10 Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016154487A Division JP2017006137A (ja) 2011-12-10 2016-08-05 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法

Publications (2)

Publication Number Publication Date
JP2015501645A JP2015501645A (ja) 2015-01-19
JP2015501645A5 true JP2015501645A5 (enExample) 2015-02-26

Family

ID=48574974

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546169A Pending JP2015501645A (ja) 2011-12-10 2012-12-10 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
JP2016154487A Pending JP2017006137A (ja) 2011-12-10 2016-08-05 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016154487A Pending JP2017006137A (ja) 2011-12-10 2016-08-05 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法

Country Status (7)

Country Link
US (1) US20140351963A1 (enExample)
EP (1) EP2788486A4 (enExample)
JP (2) JP2015501645A (enExample)
CN (1) CN104302767A (enExample)
AU (1) AU2012347498A1 (enExample)
CA (1) CA2858382A1 (enExample)
WO (1) WO2013086489A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
BR112015023439A2 (pt) * 2013-03-15 2017-07-18 Mirna Therapeutics Inc combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
US9530095B2 (en) * 2013-06-26 2016-12-27 International Business Machines Corporation Method and system for exploring the associations between drug side-effects and therapeutic indications
JP2018099031A (ja) * 2015-03-20 2018-06-28 アンジェス株式会社 ｃ−Ｍｅｔ陽性癌の判定方法
CN104784703A (zh) * 2015-04-20 2015-07-22 北京工业大学 一种基于适配体靶向递送microRNA的纳米载体及其制备方法与应用
CN105950753B (zh) * 2016-06-16 2019-10-01 朱伟 一种与肺腺癌辅助诊断相关的血浆miRNA标志物及其应用
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
KR102132222B1 (ko) * 2018-11-27 2020-07-09 강원대학교산학협력단 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
ES2534302T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CN101296702B (zh) * 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
WO2007081680A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2536423T3 (es) * 2006-01-05 2015-05-25 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cáncer de próstata
WO2008088858A2 (en) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
KR101889518B1 (ko) * 2007-10-04 2018-08-17 로슈 이노베이션 센터 코펜하겐 에이/에스 마이크로ＭＩＲｓ
AU2008310704B2 (en) * 2007-10-11 2014-03-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
CA2717030A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
ES2600165T3 (es) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2334805A1 (en) * 2008-06-04 2011-06-22 Andor Pivarcsi Skin cancer associated micrornas
CN102549166A (zh) * 2009-02-26 2012-07-04 俄亥俄州立大学研究基金会 从未吸烟者中的MicroRNA及相关材料和方法
JP2011093892A (ja) * 2009-09-30 2011-05-12 Japan Health Science Foundation がん抑制的マイクロｒｎａを含む腫瘍増殖抑制剤
US8916533B2 (en) * 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion

Similar Documents

Publication Publication Date Title
JP2015501645A5 (enExample)
Shang et al. CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy
Su et al. The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression
Peng et al. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling
Chen et al. Targetable long non-coding RNAs in cancer treatments
Wang et al. Synthetic circular multi-miR sponge simultaneously inhibits miR-21 and miR-93 in esophageal carcinoma
He et al. MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1
Liu et al. Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2
Yu et al. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells
Zhao et al. miR-630 functions as a tumor oncogene in renal cell carcinoma
Zheng et al. MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1
Lin et al. MiR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells
Shao et al. MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway
Song et al. LINC01006 regulates the proliferation, migration and invasion of hepatocellular carcinoma cells through regulating miR-433-3p/CBX3 axis
Wu et al. Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells
Sui et al. Long non-coding RNA GClnc1 promotes tumorigenesis in osteosarcoma by inhibiting p53 signaling
CN101804208A (zh) miR-451在制备治疗非小细胞肺癌药物的应用
Lin et al. An NF90/long noncoding RNA-LET/miR-548k feedback amplification loop controls esophageal squamous cell carcinoma progression
CN104587492B (zh) 长链非编码rna分子snhg18在制备治疗脑胶质瘤的药物的应用
CN106591308A (zh) 一种改善人肺腺癌厄洛替尼的耐药性的shRNA
WO2023280243A1 (zh) miR-339-增强子-靶基因网络激活模型及其应用
Ji et al. Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer
CN112359115B (zh) 与肿瘤细胞顺铂耐药性相关的miR-517a-3p及其应用
CN109453385B (zh) 一种用于治疗癌症的组合物及其应用
Wang et al. Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~ let-7d in glioblastoma